AstraZeneca Withdraws Covid Vaccine Globally, Citing Commercial Reasons: Report

Experts predict that all “monovalent” vaccines designed for the original Covid strain will be discontinued. AstraZeneca has announced a global withdrawal of its COVID-19 vaccine following reports of rare side effects. This decision comes after the British pharmaceutical company admitted that the vaccine may cause rare adverse reactions.

The vaccine, developed by AstraZeneca and Oxford University and produced as Covishield by the Serum Institute of India, has been replaced by updated vaccines that address new variants. AstraZeneca has voluntarily withdrawn its “marketing authorization” in the European Union and has ceased production of the vaccine. The company stated that it will implement similar withdrawals in other countries where the vaccine has been used.

Additionally, AstraZeneca is facing a 100 million pound lawsuit in the UK over allegations that the Covid jab led to deaths and injuries. Court documents revealed that Covishield can, in rare cases, cause Thrombosis with Thrombocytopenia Syndrome (TTS), which has been linked to at least 81 deaths in the UK. Although AstraZeneca denied any connection between the decision to withdraw Covishield and the lawsuit, the company emphasized its significant impact in saving lives during the global pandemic.

AstraZeneca highlighted that over 6.5 million lives were estimated to have been saved in the vaccine’s first year of use, and more than three billion doses were distributed worldwide. However, with the development of multiple variant Covid-19 vaccines, there is now an excess of updated vaccines available. Consequently, experts anticipate that all “monovalent” vaccines directed at the original Covid strain will be replaced by updated vaccines capable of addressing a broader range of strains.